Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SVB Leerink upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) from a market perform rating to an outperform rating in a report published on Wednesday, Briefing.com reports. The brokerage currently has $24.00 price objective on the stock. Several other research firms also recently weighed in on FDMT. HC Wainwright restated a buy rating […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) was upgraded by equities researchers at SVB Leerink from a “market perform” rating to an “outperform” rating in a note issued to investors on Wednesday, Briefing.com reports. The brokerage presently has a $24.00 price objective on the stock. SVB Leerink’s price target would suggest a potential upside […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Equities researchers at HC Wainwright raised their Q3 2023 earnings per share estimates for 4D Molecular Therapeutics in a research note issued on Thursday, August 10th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.78) for the quarter, […]
Chardan Capital restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report released on Friday morning, Benzinga reports. The firm currently has a $31.00 target price on the stock. A number of other equities research analysts have also issued reports on FDMT. HC Wainwright reiterated a buy […]
HC Wainwright restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock. Other research analysts also recently issued reports about the company. Chardan Capital boosted their price objective on […]